@mattbagg will be on two different panels at @discoveryconsf on April 18th:
11-11:45am: Initiatives in Novel Chemistry: The Hunt for New Compounds in Extraordinary Places
2-2:45pm: Black Market / Grey Data: Finding Reliable Data in Psychedelics
https://t.co/N9Z7UN7mFH
"Exploring MDMA on Valentine's Day" is in two days on Feb 14th from 9-10am PST! Join @mattbagg in the exploration of the science and research behind MDMA. Register with this link:
https://t.co/LJvGmzpbXV
We'd like to extend our congratulations to the @Lykos_PBC team on the fantastic news that the FDA has accepted their new drug application for MDMA-assisted therapy for PTSD and granted it priority review. Groundbreaking!
#BREAKING: We are proud to announce the @FDA acceptance and priority review of our new drug application (NDA) filing for our investigational therapy for post-traumatic stress disorder #PTSD in adults. Learn more: https://t.co/WbvgbygG1S
Join us on Valentine's Day for "Exploring MDMA on Valentine's Day", a fireside chat featuring @mattbagg, moderated by @HashmallJoe. Glimpse into the future of entactogen research. Hosted by Dragonfly 44 Capital.
Event is free, register here: https://t.co/LJvGmzpbXV
Thank you @Psyched_Alpha and team for your work of this psychedelic drug development bullseye chart. This chart features four of Tactogen's molecules in development.
Bullseye Chart: The Psychedelic Drug Development Pipeline
@MichaelHaichin and @NoahJSmith98 have produced the latest iteration of our psychedelic drug dev. bullseye chart.
Access and download the full-size chart here:
https://t.co/iOMggjhgCw
Paper published today co-authored by @mattbagg. Major points highlight some focus of our work. Key to why we focus on novel entactogens:
https://t.co/XrJ8mw4tWS
We're excited to announce that @mattbagg will be appearing at two events in the coming months.
ISRP: February 16-18 in New Orleans. https://t.co/ppRZvn8FJh
SXSW: March 8-11 in Austin, Texas. Featuring @TimSchlidt , @BellevueDoc, and @RachelNuwer. https://t.co/42sDfHIyyQ
Thank you @doubleblindmag for featuring @mattbagg with his in-depth analysis of Moxy (5-MeO-MiPT). Tactogen opposed the DEA's proposed ban on Moxy and other tryptamines in 2022. https://t.co/Ya0lmluM2H
“Our goal is to make medicines that are derived from psychedelics that are safer and gentler, more effective and more accessible” said
@mattbagg of @TactogenInc. @Delix_tx @TheBorisLab @calyxlaw https://t.co/YGDf2UqWP3
BREAKING: MAPS PBC Files New Drug Application for MDMA-Assisted Therapy for PTSD
Filing marks the first NDA submission for any psychedelic-assisted therapy
https://t.co/YUcpnvNXLL
@HamiltonMorris released his podcast interview with @mattbagg.
"For years I've wanted to interview Dr. Matthew Baggott, one of the word's leading experts on the human psychopharmacology and molecular neuropharmacology of MDMA and related entactogens."
https://t.co/tqZ0V7NeFQ
The first session of the I Feel Love book club is available for replay. Featuring author @RachelNuwer and neuroscientist Gül Dölen.
https://t.co/PqvN3hEd7D